AFC
AZN icon

AFT Forsyth & Company’s AstraZeneca AZN Stock Holding History

AFT Forsyth & Company’s Portfolio AZN Stock Details AZN Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2013
Q3 		$57K Hold
1,100
– – 0.07% 165
2013
Q2 		$52K Buy
+1,100
New +$56K 0.07% 160

Other funds holding AZN

Wellington Management Group
Wellington Management Group Boston, Massachusetts $535B AUM 26.23% 1-Year Est. Return
Allianz Asset Management
Allianz Asset Management Munich, Germany $95.4B AUM 38.74% 1-Year Est. Return
Fidelity Investments
Fidelity Investments Boston, Massachusetts $1.9T AUM 41.92% 1-Year Est. Return
U
UBS Zurich, Switzerland $136B AUM 16.36% 1-Year Est. Return
Hotchkis & Wiley Capital Management
Hotchkis & Wiley Capital Management Los Angeles, California $32.4B AUM 17.21% 1-Year Est. Return
EIP
Epoch Investment Partners New York $16.5B AUM 24.3% 1-Year Est. Return
MAA
Managed Account Advisors Jersey City, New Jersey $121B AUM 7.32% 1-Year Est. Return
Federated Hermes
Federated Hermes Pittsburgh, Pennsylvania $61.5B AUM 30.7% 1-Year Est. Return
SCCM
Schafer Cullen Capital Management New York $491M AUM 41.48% 1-Year Est. Return
Arrowstreet Capital
Arrowstreet Capital Boston, Massachusetts $185B AUM 39.58% 1-Year Est. Return

AFT Forsyth & Company's AZN Position: Q3 2013 in Review

AFT Forsyth & Company held its AstraZeneca (AZN) position steady in Q3 2013 at 1,100 shares worth $57K. The position accounts for 0.07% of the portfolio, ranked #165.

AFT Forsyth & Company first reported a position in AZN in Q2 2013 and has held it in 2 quarters since. 343 funds tracked by Wall St. Rank hold AZN as of Q3 2013.

  • AFT Forsyth & Company held 1,100 shares of AstraZeneca worth $57K as of Q3 2013.
  • AFT Forsyth & Company left its AstraZeneca share count unchanged in Q3 2013.
  • AstraZeneca made up 0.07% of AFT Forsyth & Company's portfolio in Q3 2013, its #165 holding.
  • AFT Forsyth & Company first reported a position in AstraZeneca in Q2 2013 and has held it in 2 quarters since.
  • 343 funds tracked by Wall St. Rank held AstraZeneca as of Q3 2013.

Based on AFT Forsyth & Company's 13F filing for Q3 2013, filed 8 Nov 2013.